Institut Jerome Lejeune   Report issue

Academic/Hospital Phase 3
Founded: Paris France (1997)

Organization Overview

First Clinical Trial
2000
NCT00294593
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Institut Jerome Lejeune | Institut Jerome Lejeune, Paris, France

Active Ingredients

Drugs in Phase 3 Trials (2)

leucovorin (2 trials)

levothyroxine (Synthroid) (1 trial)

Drugs in Other Trials (1)

l-epigallocatechin (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Down Syndrome (Phase 3)

Syndrome (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 3